Indications |
Oral Pain and inflammation associated with musculoskeletal and joint disorders Adult: 1 g as a single dose in the evening, followed by 0.5-1 g in the morning if necessary. Patients <50 kg: Less likely to require >1 g daily. Elderly: 500 mg daily may be adequate in certain patients. Max: 1 g daily.
|
||||||
Contraindications |
Active peptic ulceration; severe hepatic impairment; hypersensitivity; patients in whom other NSAIDs or aspirin are likely to induce asthma, angioedema, pruritus or urticaria. Pregnancy (3rd trimester), lactation. Perioperative pain in the setting of CABG. | ||||||
Warnings / Precautions |
Pre-existing CV risk factors or disease; fluid retention, CHF, hypertension. History of GI disease (bleeding or ulcers). Elderly or debilitated patients. Other forms of asthma. Hepatic impairment; closely monitor patients with any abnormal LFT. Renal impairment; rehydrate patient prior to therapy and closely monitor renal function. Withhold for at least 4-6 half-lives prior to surgical or dental procedures. | ||||||
Adverse Reactions |
Abdominal pain, dyspepsia, diarrhoea, nausea, flatulence, gastritis, vomiting, xerostomia, stomatitis; headache, tinnitus, dizziness; rash, pruritus; constipation; oedema; insomnia, fatigue, nervousness, somnolence; diaphoresis. Potentially Fatal: Exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Severe hepatic reactions (e.g. fulminant hepatitis, liver failure). Anaphylactoid reactions. |
||||||
Overdose Reactions |
Symptoms: Drowsiness, epigastric pain, lethargy, nausea, vomiting. Rarely, acute renal failure, coma, hypertension and respiratory depression. Management: Supportive and symptomatic. 6-MNA is not dialysable. | ||||||
Drug Interactions |
Antihypertensive effects of hypotensive agents may be reduced. May increase ciclosporin levels. Increased risk of seizures with fluoroquinolones. May reduce efficacy of diuretics. May diminish the cardioprotective effect of acetylated salicylates. Alcohol may enhance gastric mucosal irritation. Potentially Fatal: Increased risk of GI ulceration with corticosteroids. May increase lithium levels/toxicity. Severe bone marrow suppression, aplastic anaemia and GI toxicity may occur with methotrexate. Increased risk of bleeding with anticoagulants (e.g. warfarin, heparin, LMWHs) and antiplatelet agents (e.g. ticlopidine, clopidogrel, aspirin, abciximab, dipyridamole, eptifibatide, tirofiban). Absorption may be reduced with colestyramine (and other bile acid sequestrants). See Below for More nabumetone Drug Interactions |
||||||
Food Interactions |
Bioavailability of 6-MNA is unaffected by food; peak serum concentrations may be increased. Avoid herbs/food with antiplatelet activity e.g. alfalfa, anise, bilberry, grapeseed, green tea, bladderwrack, turmeric, bromelain, cat's claw, celery, ginkgo biloba, coleus, cordyceps, dong quai, evening primrose, feverfew, fenugreek, garlic, ginger, red clover, horse chestnut, ginseng, guggul, horse chestnut seed, horseradish, licorice, prickly ash, reishi, sweet clover, white willow. | ||||||
Mechanism of Actions |
Nabumetone is a weak cyclooxygenase (COX) inhibitor and is converted in the liver to 6-methoxy-2-naphthylacetic acid (6-MNA), a potent inhibitor of COX, the enzyme responsible for prostaglandin synthesis. This results in the reduction of prostaglandin levels and alleviation of pain and inflammation. Absorption: Well absorbed from the GI tract (oral). Distribution: Diffuses into synovial fluid; crosses the placenta; enters breast milk. Protein-binding: >99% (6-MNA). Metabolism: Extensively hepatic; rapidly metabolised to 6-MNA; further metabolism by O-methylation and conjugation. Excretion: Via urine (as inactive or conjugated metabolites). Elimination half-life of 6-MNA: 22-27 hr (adult), 25-34 hr (elderly). |
||||||
Administration |
May be taken with or without food. (May be taken w/ meals to reduce GI distress.) |
||||||
Storage Conditions |
Oral: Store at 20-25°C (68-77°F). | ||||||
ATC Classification |
M01AX01 - nabumetone ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products. | ||||||
Storage |
Oral: Store at 20-25°C (68-77°F). | ||||||
Available As |
|
Nabumetone
Post Review about Nabumetone Click here to cancel reply.
Nabumetone Containing Brands
Nabumetone is used in following diseases
Drug - Drug Interactions of Nabumetone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.